DOCSLIB.ORG

Introducing the IMED Biotech Unit

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Introducing the IMED Biotech Unit Introducing the IMED Biotech Unit What science can do Circulating tumour DNA AstraZeneca has pioneered the use of circulating tumour DNA (ctDNA) in the diagnosis of cancer. Pieces of DNA break off from a tumour and circulate in the bloodstream where they can be analysed to give genetic information about a patient’s tumour. This allows healthcare professionals to determine the right treatment for the patient using a non-invasive blood test. 1 What science can do At AstraZeneca, our purpose is to push the boundaries of science to deliver life-changing medicines. We will achieve this by placing science at the centre of everything we do. The future of treatment for many of today’s diseases lies in uncovering mechanisms that are newly emerging or still to be discovered. We believe the best way to help patients is to focus on breakthrough science to identify these mechanisms and then use our distinctive capabilities to develop novel, targeted therapies. Our approach to Research & Development It’s science that Distinctive science starts in our two biotech units, which conduct innovative discovery research and early-stage development from compels us to push the initial target selection to Phase II trial completion before transitioning to Global Medicines Development. boundaries of what is possible. We trust in the IMED Biotech Unit MedImmune Global Medicines potential of ideas and Focuses on using state-of-the Focuses on biologics across our Development art discovery platforms and core areas and pioneers innovative pursue them, alone and translational science in small research using unparalleled expertise The science engine room that drives with others, until we molecules, oligonucleotides and in protein engineering, translational late-stage development of our other emerging technologies. sciences and immunology. innovative pipeline, transforming have transformed the exciting science into valued new medicines and ensuring patients treatment of disease. around the world can access them. 2 3 Our IMED Biotech Unit “Now is a great time to be a scientist in AstraZeneca. Working across a range of therapy areas, our IMED teams are focused on translating the really cool science that is happening in our labs into the next generation of medicines We are committed to driving scientific advances that patients need. To make this happen, we need great partners who share in small molecules, oligonucleotides and other our passion for science and who have the drive and determination to meet the emerging technology platforms to push the unmet needs of patients around the world.” boundaries of medical science. Mene Pangalos, EVP, IMED Biotech Unit Each year we invest in excess Partnering and collaboration creating a permeable research of $1bn on discovering and is a way of life for our teams. environment where scientists developing the next generation We work alongside scientists can more freely share their ideas of life changing medicines, from at many of the world’s leading and collaborate on projects with initial target selection through academic institutions to increase the best external scientists. We to the end of Phase 2 trials. our understanding of disease remain committed to openness We employ over 2,000 physiology and help identify and accessibility, and will continue scientists and undertake potential new drugs. to identify new and innovative research on a truly global scale, ways to connect the great science operating vibrant science We are pioneering new happening in our labs with the centres across three continents. approaches to open innovation, best external science around. We believe in the potential of ground-breaking science to transform the lives of patients. We do this by focusing on three key priorities. Fostering a culture where Creating an environment open Challenging conventional science thrives – one for innovation - where our thinking - we encourage our that is dynamic, agile and teams work side by side with our people to apply scientific rigour in entrepreneurial. academic and industry partners to challenging the way we do things. make the next breakthrough. 4 5 Where science thrives We are achieving scientific leadership through a Focusing on quality dynamic, agile and entrepreneurial culture that not quantity feels like a biotech but has the resources of a major A comprehensive review of our IMED small-molecule drug global pharmaceutical company. projects took place from between 2005 and 2010. This helped us identify the most important factors for project success and pipeline quality. We call this our 5R framework. The 5R framework emphasises quality rather than quantity Inspiring great scientists in our research and development. That’s why a sixth critical factor is having the right culture. IMED has established a culture where our teams are ‘truth seeking’ in their behaviour Our plan to achieve scientific leadership rests on our ability to and rigorous in their approach to asking the critical ‘killer’ attract and retain the best scientists. We continue to attract ~2,500 questions. Rather than being rewarded for hitting the next senior scientists from academia and industry. Why? Because milestone, our scientists are rewarded for thinking about the quality of our science and the potential of our pipeline make people with a what it would take to deliver a viable, differentiated medicine. passion for science the IMED Biotech unit a great place to work. Both our IMED teams and our Early Stage Portfolio At the same time, we are committed to inspiring the next Committee (ESPC) use this framework to ensure we are generation of scientists by giving them opportunities to develop progressing the right projects, asking the right questions their skills and follow the science they are passionate about. and making the right decisions at key review points Almost throughout the drug development process. This approach is now embedded into the way our teams work and is used by the ESPC to review and approve pipeline progressions. 1,000 Building our scientific reputation papers published Our scientists and teams are encouraged to publish their Our 5R framework over 2014 and 2015 work in peer reviewed journals. Demonstrating the quality of the research conducted in our labs, particularly in high Right target quality and high impact journals, is an essential element in • Strong link between target and disease building our scientific reputation and our plans to achieve • Differentiated efficacy scientific leadership for AstraZeneca. It is also a critical • Available and predictive biomarker Over consideration for recruiting and retaining the best scientists from around the world. Right tissue • Adequate bioavailability and tissue exposure • Definition of PD biomarkers 45 • Clear understanding of preclinical and clinical PK/PD High Impact publications Delivering a step change in R&D • Understanding of drug-drug interactions in past two years productivity and output Right safety Since it was formed in 2010, the IMED Biotech Unit has helped • Differentiated and clear safety margins deliver sustainable improvements in R&D productivity across • Understanding of secondary pharmacology risk AstraZeneca. In recent years, we have created a leaner, simpler • Understanding of reactive metabolites, Over organisation, focused on driving distinctive science across our genotoxicity, drug-drug interactions key therapy areas. • Understanding of target liability Through a rigorous focus on great science, we have developed Right patients $1bn a robust clinical pipeline across our core therapy areas of • Identification of the most responsive patient oncology, respiratory and inflammation and cardiovascular population invested in scientific disease. We also continue to progress the most promising • Definition of risk-benefit for given population research each year projects in neuroscience in collaboration with partners and in small molecule anti-infectives through our standalone company, Entasis Therapeutics. Right commercial opportunity • Differentiated value proposition versus future standard of care • Focus on market access, payer and provider Lessons learned from the fate of AstraZeneca’s drug • Personalised healthcare strategy, including pipeline: a five-dimensional framework Cook et al diagnostic and biomarkers Nature Reviews Drug Discovery 13, 419–431 (2014) 6 Our therapeutic focus The future of treatment for many of today’s diseases Cardiovascular & Metabolic lies in uncovering mechanisms that are newly Diseases iMed emerging or are still to be discovered. Our strategy in CVMD focuses on ways to reduce morbidity, mortality and organ damage by addressing multiple risk factors across cardiovascular (CV) disease, diabetes and chronic kidney disease indications. The patient-centric approach is reinforced by science-led lifecycle management programmes and technologies, including early research into regenerative methods. We believe the best way to help patients is to focus on Cardiovascular and breakthrough science to discover Metabolic diseases these mechanisms and develop novel, targeted therapies that interact with them. Our focus in IMED is on the following three Oncology iMed main therapy areas: Our vision is clear. To help patients by redefining the cancer- treatment paradigm, with the aim of bringing six new cancer medicines to patients between 2013 and 2020. A broad pipeline of next-generation medicines is focused principally on four disease areas – breast, ovarian, lung and Oncology haematological cancers. We have one of the broadest and deepest
Load more

Recommended publications
  • The Scientific Organizing Committee Gratefully Acknowledges the Pharmaceutical and Biotechnology Industry for Their Generous Support of WCBP 2019
    The Scientific Organizing Committee gratefully acknowledges the pharmaceutical and biotechnology industry for their generous support of WCBP 2019: Strategic Diamond Program Partners F. Hoffmann-La Roche Ltd. Genentech, a Member of the Roche Group Strategic Platinum Program Partners Amgen Inc. Biogen MedImmune, A member of the AstraZeneca Group Strategic Gold Program Partners Eli Lilly and Company Merck & Co., Inc. Novo Nordisk A/S Pfizer, Inc. Strategic Silver Program Partner Sanofi 1 Gold Program Partner Bill and Melinda Gates Foundation Silver Program Partners BioMarin Pharmaceutical Inc. Bristol-Myers Squibb Company GlaxoSmithKline Jazz Pharmaceuticals Bronze Program Partner Seattle Genetics, Inc. Friend of CASSS Janssen R&D, LLC 2 The Scientific Organizing Committee gratefully acknowledges the Program Partners and Exhibitors for their generous support of WCBP 2019: Diamond Program Partners Agilent Technologies Catalent Pharma Solutions Eurofins Pharma Discovery Services ProteinSimple, a Bio-Techne brand Thermo Fisher Scientific Waters Corporation Platinum Program Partners BioAnalytix SCIEX Bronze Program Partner Bruker Corporation 3 The Scientific Organizing Committee gratefully acknowledges the Exhibitors for their generous support of WCBP 2019: Exhibitor Partners 908 Devices Inc. NanoImaging Services Agilent Technologies New England Biolabs Associates of Cape Cod, Inc. Postnova Analytics Inc. BioAnalytix Inc. Pressure BioSciences Inc. Bruker Corporation Protein Metrics, Inc. Catalent Pharma Solutions ProteinSimple, a Bio-Techne brand Charles River Laboratories ProZyme, A part of Agilent Covance, Inc. RedShift BioAnalytics, Inc. Cygnus Technologies Rockland Immunochemicals, Inc. Envigo SCIEX Eurofins BioPharma Product Testing SGS Life Science Services Eurofins Pharma Discovery Services Shimadzu Scientific Instruments, Inc. FortéBio - Biologics by Molecular Devices Thermo Fisher Scientific GE Healthcare Life Sciences U.S.
    [Show full text]
  • The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry
    The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry By: Maitri Punjabi Honors Thesis Economics Department The University of North Carolina at Chapel Hill March 2016 Approved: ______________________________ Dr. Jonathan Williams Punjabi 2 Abstract This paper analyzes the effect of the changing nature of innovation on pharmaceutical firm market value from the years 1987 to 2010 by using U.S. patent and claim data. Over the years, firms have started shifting focus from primary innovation to secondary innovation as new ideas and new compounds become more difficult to generate. In this study, we analyze the impact of this patent portfolio shift on the market capitalization of pharmaceutical firms. After using firm fixed effects and the instrumental variable approach, we find that there exists a strong positive relationship between secondary innovations and the market value of the firm– in fact, we find a stronger relationship than is observed between primary innovation and market value. When focusing on the different levels of innovation within the industry, we find that this relationship is stronger for less-innovative firms (those that have produced fewer patents) than it is for highly- innovative firms. We also find that this relationship is stronger for firms that spend less on research and development, complementing earlier findings that research productivity is declining over time. Punjabi 3 Acknowledgements I would primarily like to thank my adviser, Dr. Jonathan Williams, for his patience and constant support. Without his kind and helpful attitude, this project would have been a much more frustrating process. Through his knowledge of the industry, I have gained valuable insight and have learned a great deal about a unique and growing field.
    [Show full text]
  • United States Securities and Exchange Commission Form 10-K Shire Pharmaceuticals Group
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ፤ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 1999 អ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-29630 SHIRE PHARMACEUTICALS GROUP PLC (Exact name of registrant as specified in its charter) England and Wales (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification No.) N.A. East Anton, Andover, Hampshire SP10 5RG England (Address of principal executive offices) (Zip Code) 44 1264 333455 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depository Shares, each representing Nasdaq National Market 3 Ordinary Shares, 5 pence nominal value per share Securities registered pursuant to Section 12(g) of the Act: None (Title of class) Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ፤ No អ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant's knowledge, in definitive proxy or information statements incorporated by reference to Part III of this Form 10-K or any amendment to this Form 10-K.
    [Show full text]
  • Dyax Corp. 300 Technology Square Cambridge, MA 02139 617 225-2500
    Dyax Corp. 300 Technology Square Cambridge, MA 02139 617 225-2500 www.dyax.com Other Offices Dyax SA, Liege, Belgium ADVANCING NOVEL THERAPEUTIC PRODUCTS Dyax Corp. Annual Report 2003 Corporate Information Dyax Achievements 2003 Dyax Goals 2004 Directors Executive Officers and Stock Listing Henry E. Blair Key Employees Common stock has been traded on the Nasdaq Stock Market Advances in Clinical Development Clinical Development Chairman, President and Henry E. Blair* under the symbol DYAX since our initial public offering in Milestones Chief Executive Officer, Chairman, President and August 14, 2000. DX-88/Hereditary Angioedema Dyax Corp. Chief Executive Officer DX-88/Hereditary Constantine E. Stephen S. Galliker, CPA* The following table gives the quarterly high and low sales G Completed 9-patient Phase II trial, met primary endpoints Angioedema Anagnostopoulos, Ph.D. EVP Finance and prices of our common stock for the last three years. G Genzyme Corporation joined Dyax as joint venture partner Managing General Partner, Administration and G Complete Phase II 2001 2002 2003 G Gateway Associates, LP Chief Financial Officer Completed 3 of 4 dose cohorts in 48-patient Phase II EDEMA1 trial EDEMA1 study High Low High Low High Low G Susan B. Bayh, J.D. Lynn G. Baird, Ph.D.* Initiated Phase II EDEMA2 trial G Periodically observe James W. Fordyce SVP Development First Quarter $20.94 $6.56 $11.38 $3.10 $2.25 $1.52 G Orphan Drug designation granted in U.S. and Europe effects of repeat dosing in Phase II EDEMA2 Managing Partner, Robert C. Ladner, Ph.D. Second Quarter $19.99 $6.81 $ 4.68 $3.20 $4.90 $1.67 Fordyce & Gabrielson, LLC SVP and Chief DX-88/On-Pump Open Heart Surgery (CABG) study Third Quarter $21.24 $6.05 $ 4.20 $1.65 $7.50 $2.58 Mary Ann Gray, Ph.D.
    [Show full text]
  • 2016 Medicines in Development for Rare Diseases a LIST of ORPHAN DRUGS in the PIPELINE
    2016 Medicines in Development for Rare Diseases A LIST OF ORPHAN DRUGS IN THE PIPELINE Autoimmune Diseases Product Name Sponsor Official FDA Designation* Development Status Actemra® Genentech treatment of systemic sclerosis Phase III tocilizumab South San Francisco, CA www.gene.com Adempas® Bayer HealthCare Pharmaceuticals treatment of systemic sclerosis Phase II riociguat Whippany, NJ www.pharma.bayer.com ARA 290 Araim Pharmaceuticals treatment of neuropathic pain in patients Phase II Tarrytown, NY with sarcoidosis www.ariampharma.com ARG201 arGentis Pharmaceuticals treatment of diffuse systemic sclerosis Phase II (type 1 native bovine skin Collierville, TN www.argentisrx.com collagen) BYM338 Novartis Pharmaceuticals treatment of inclusion body myositis Phase III (bimagrumab) East Hanover, NJ www.novartis.com CCX168 ChemoCentryx treatment of anti-neutrophil cytoplasmic Phase II (5a receptor antagonist) Mountain View, CA auto-antibodies associated vasculitides www.chemocentryx.com (granulomatosis with polyangitis or Wegener's granulomatosis), microscopic polyangitis, and Churg-Strauss syndrome * This designation is issued by the FDA's Office of Orphan Products Development while the drug is still in development. The designation makes the sponsor of the drug eligible for entitlements under the Orphan Drug Act of 1983. The entitlements include seven years of marketing exclusivity following FDA approval of the drug for the designated use. Medicines in Development: Rare Diseases | 2016 1 Autoimmune Diseases Product Name Sponsor Official FDA
    [Show full text]
  • An Emerging National Resource for Clinical Research and Your Healthcare Partner in Personalized Medicine Innovation
    An Exclusive Membership Look into Colorado To visualize improving the world around us Fisher Scientifi c, part of Thermo Fisher Scientifi c, the world leader in serving science, is pleased to have the opportunity to partner with the Colorado BioScience Association and act as primary supplier of laboratory products, safety supplies, equipment, chemicals, reagents and a host of services. Fisher Scientifi c understands today’s challenging environment and has capabilities that align with CBSA’s strategic goals going beyond just providing products to o ering Colorado BioScience Association members access to customized programs to fi t their specifi c needs from start-up to scale-up. 1.800.766.7000 • Fax: 1.800.926.1166 • www.fi shersci.com 2 BIOSCIENCECOLORADO 2014-2015 Litho in U.S.A. 13_0280 JJ/KJ COLOR ADO 2014-2015 Drawing People & Data Together to Benefit Human Health 10 22 26 14 6 CONTENTS 06 Mobile Health in Colorado: Where “Big Data” Sparks Big Ideas 10 Biodesix Harnesses Machine Learning and Analytics to Tackle Multivariate Diagnostics 14 Bioscience in Colorado Continues to Shine with U.S. Senator Michael Bennet 16 Color ado Life Science Assets: A Sophisticated Repertoire of Clinical-Stage Therapeutic, Device and Diagnostic Products 22 Webb-Waring Biomedical Research Program 26 F ound in Translation: Rocky Mountain Lions Eye Institute Translational Research Programs Focus on Innovative Treatment of Eye Diseases 30 Connecting the Dots: Tech Transfer Offices Connect Research and Marketplace to Stimulate the State's Economy 33 Colorado by the Numbers: Financing and Acquisitions 36 Grant Programs: Innovation Engines 48 Colorado Bioscience Industry Directory 2014-2015 BIOSCIENCECOLORADO 3 We Know Workforce elcome to the Colorado BioScience Association’s eleventh anniversary edition of Bioscience Colorado.
    [Show full text]
  • Immunocore and Medimmune Announce New Collaboration to Conduct Immuno-Oncology Combination Trials in Melanoma
    PRESS RELEASE – IMMUNOCORE LIMITED Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma (Oxford, UK, 16 April 2015) Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer and other diseases, and MedImmune, the global biologics research and development arm of AstraZeneca, today announced that they have entered into a second collaboration. Under the terms of the agreement, Immunocore will conduct a Phase Ib/II clinical trial combining MedImmune’s investigational checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100, Immunocore’s lead T-cell receptor based investigational therapeutic, for the potential treatment of patients with metastatic melanoma. MedImmune has an exclusive relationship with Immunocore for the development of IMCgp100 in combination with MEDI4736 and/or tremelimumab, and will have first right of negotiation for the future commercial development of these combinations for tumours expressing gp100. Immunocore and MedImmune will collaborate to establish a dosing regimen for IMCgp100 combined with MEDI4736 and/or tremelimumab, as part of the Phase Ib study. The Phase II study will assess the safety and efficacy of the different combinations. The companies have a pre-existing research collaboration and licensing agreement, announced in January 2014, to develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology. “We are pleased to expand our partnership with Immunocore, a leader in the discovery and development of novel T-cell receptor-based drugs, to include this combination clinical trial in melanoma,” said Dr. Ed Bradley, Senior Vice President and Head of the Oncology Innovative Medicines unit, MedImmune.
    [Show full text]
  • Summit for Clinical Ops Executives
    Organized by Register Today! FINAL AGENDA 7th Annual February 23 - 25, 2016 | Hyatt Regency Miami, Miami, FL Back in SUMMIT FOR CLINICAL OPS EXECUTIVES Miami! February 23-24 February 24-25 Global Site Selection, Feasibility Assessment, Improving Site-Study Activation and Performance Operations and Site Management Patient Engagement, Enrollment and Retention through Enrollment Planning and Patient Recruitment Communities and Tech Clinical Trial Forecasting and Budgeting Managing Outsourced Clinical Trials Implementing Risk-Based Monitoring (Part 1) Implementing Risk-Based Monitoring (Part 2) Clinical IT Strategy and Governance Clinical Data Technology and Integration Managing Late Stage Research, Observational Leveraging Existing Data for Clinical and Studies and Registries Observational Research Symposia - February 23-24 Managing Biomarker-Driven Clinical Trials NEW Clinical Research Statistics for Non-Statisticians NEW Event Features BEST 12 Conferences Clinical Informatics News Best Practices Awards P R S 2 Plenary Keynote Sessions Dedicated Exhibit Hall Hours & A E C T I C Networking Functions 3 Short Courses RAC RAC RAC P T P T P T T IC T IC T IC S E S E S E Interactive Breakout Discussions 2 New Symposia E S E S E S B B B 2 n 0 1 o i 2 2 4 t 0 E 0 R H n 1,000+ Industry Leaders Expected in 2016 1 E o e 1 E 4SCOPEsummit.comn M 4 N W I N N o r a b l e N O M I PREMIER SPONSORS Event-at-a-Glance Monday, February 22, 2016 Pre-Conference Short Courses (Optional, Separate Registration Required) 1.
    [Show full text]
  • The Future of Biomanufacturing
    THE FUTURE OF BIOMANUFACTURING WELCOME TO A PLACE THAT DELIVERS. HEADER 2 | BIOMANUFACTURING WELCOME TO EUROPE’S MOST SIGNIFICANT CLUSTER OF BIOMANUFACTURING. Liverpool City Region is home to the world’s biggest pharmaceutical players. It is also one of the world’s longest established biomanufacturing centres, chosen by the UK government in the 1940s for the largest penicillin manufacturing plant in the world. Major companies continue to build on this long-tradition and reinvest in new world-class facilities. Our formula for pharma manufacturing success is clear. Liverpool City Region sits at the centre of the UK’s chemical engineering industry; is part of a major centre for health and life sciences and is driving the advanced manufacturing sector through digital innovation. The convergence of these assets has a catalytic impact on the availability of the science, technology and engineering talent that underpins biomanufacturing. Most importantly though, a committed partnership of local organisations is supporting existing manufacturers and the wider supply-chain, through programmes to invest in the infrastructure, facilities and skills that the sector needs to succeed. Welcome to your future-proofed business location. BIOMANUFACTURING | 3 M65 M 6 SEFTON M 6 2 6 6 M M 6 1 M58 62 M M 6 GLASGOW M602 EDINBURGH M MANCHESTER 5 7 M 6 GLOBAL 0 TRADE KNOSLEY ROUTES ST. HELENS 0 6 M NEWCASTLE LIVERPOOL M 62 6 15 M 10 11 M62 12 14 13 HALTON LIVERPOOL CITY REGION LEEDS 56 MANCHESTER HULL M 1 AIRPORT MANCHESTER 7 RIVER 4 M MERSEY 2 9 5 8 SHEFFIELD IRRAL 5 3 3 M LIVERPOOL JOHN 6 LENNON AIRPORT NOTTINGHAM AL CAN 6 SHIP STER CHE MAN BIRMINGHAM 6 M5 CARDIFF BRISTOL LONDON PLYMOUTH SOUTHAMPTON 4 | BIOMANUFACTURING M65 M 6 SEFTON M 6 2 6 6 M M 6 1 M58 62 M M 6 M602 M MANCHESTER 5 7 M 6 GLOBAL 0 TRADE KNOSLEY ROUTES ST.
    [Show full text]
  • Medimmune Delivering the Next Wave of Scientific Innovation
    MedImmune Delivering the next wave of scientific innovation Bahija Jallal, Executive Vice President, MedImmune Building on the fundamentals Next wave of science 1 – MedImmune MedImmune has a 25+ year history in biologics; pioneering scientists are still driving discoveries today RespiGam 1996 2002 Gail Wasserman, PhD Mike McCarthy, MD, MPH, MS Tris Vaughan, PhD 1998 Biopharmaceutical Dev. Infectious Diseases / Vaccines Antibody Discovery & Pennsylvania State Uni. U. Maryland University College Protein Engineering Montclair State Uni. Georgetown U. School of Med. 2011 University of Toronto University of Leeds 1998 2003 2006 JoAnn Suzich, PhD Mark Schenerman, PhD Hong Jin, PhD Infectious Disease / Biopharmaceutical Dev. Infectious Diseases / Vaccines Cornell University Vaccines Purdue University University of Florida Northwestern Uni. 2009 2012 Glasgow Uni. 2 – MedImmune MedImmune continues to attract world class scientists with strong expertise in areas of interest Yong-Jun Liu, MD, PhD Jack Ratchford, MD Head of Research Neuro-Immunology Baylor Research Institute Chief Scientific Johns Hopkins U. School of Medicine Officer and Director of Immunology Columbia U. College of Physicians and Research Surgeons David Howe, MD Jacob Wesley, PharmD, MS Autoimmunity Oncology Cornell University Johns Hopkins University University of Toronto University of Maryland Edinburgh U. Medical School Brett Hall, PhD Eliezer Katz, MD Translational Science - Oncology Neuro-Inflammation West Virginia University U. of Massachusetts Medical Center Ohio State University
    [Show full text]
  • Shire: a Focused Global Pharmaceutical Company Focusing on a Bright Future Shire Pharmaceuticals Group Plc the Shire Mission
    Shire Pharmaceuticals Group plc Annual review and summary financial statement 2003 Shire: a focused global pharmaceutical company Focusing on a bright future Shire Pharmaceuticals Group plc The Shire mission Our mission is to become the leading company in meeting the needs of the specialist physician. We want to achieve this by developing and Contents 01 Financial highlights marketing products of the highest quality 02 Chairman’s statement 04 Chief Executive Officer’s review for the treatment of serious diseases, 06 Product portfolio 07 Product development pipeline which are treated by medical specialists. 08 Operating review 22 CSR: Corporate and social responsibility 24 Financial review We aim to provide high quality and effective 28 Board of Directors 30 The Executive Committee products that enhance the health and 32 Directors’ remuneration report 44 Corporate governance quality of life of people around the world statement Financial Statements and contribute to the long-term business 48 Statement of Directors’ responsibilities – Report of success of our Company, to the benefit independent auditors 49 Consolidated balance sheets 50 Consolidated statement of all our stakeholders. of operations 51 Consolidated statements of changes in shareholders’ equity We are driven by the needs of all our 52 Consolidated statements of cash flows stakeholders: patients, their families and 53 Notes to the consolidated financial statements 87 Five-year review caregivers, doctors and medical specialists, 88 Summary financial statement 93 Notes to summary employees and partner companies, the financial statement community in which we live and work and, Other 94 Shire head office and main operating locations of course, our shareholders.
    [Show full text]
  • Medimmune Advancing Science for Better Health
    MedImmune Advancing Science for Better Health Annual Report 2005 On the Cover SCIENCE, TECHNOLOGY AND INNOVATION ARE AT THE HEART OF MEDIMMUNE’S RESEARCH AND DEVELOPMENT EFFORTS, HELPING TO PROVIDE THE ADVANCES IN MEDICINE NEEDED FOR PATIENTS. FROM LEFT TO RIGHT, SUSAN WILSON, RESEARCH MANAGER I, WENDY WHITE, SENIOR SCIENTIST I, FRAN PALMER-HILL, RESEARCH MANAGER I, AND JOANN SUZICH, SENIOR DIRECTOR, MOLECULAR BIOLOGY AND BIOCHEMISTRY, ARE MEMBERS OF THE ORIGINAL TEAM AT MEDIMMUNE WHO PIONEERED THE DEVELOPMENT OF VIRUS-LIKE PARTICLE TECHNOLOGY IN THE MID-1990s THAT IS NOW INCORPORATED INTO HUMAN PAPILLOMAVIRUS (HPV) VACCINES IN DEVELOPMENT AT GLAXOSMITHKLINE (GSK). THIS HPV VACCINE TECHNOLOGY IS AN EXAMPLE OF OUR CONTINUING PRODUCT DEVELOPMENT PROCESSES THAT, WE BELIEVE, MAY RESULT IN SCIENTIFIC ADVANCES IN OTHER AREAS, SUCH AS INFLUENZA VACCINES AND THE TREATMENT AND PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV). Financial Highlights (in millions, except per share data) 20051,2 20042 2003 20023,4 20014 CONSOLIDATED STATEMENT OF OPERATIONS DATA Total Revenues $1,244 $1,141 $1,054 $ 853 $ 621 Gross Profit 884 758 703 589 443 Research & Development 385 327 156 148 83 Net (Loss) Earnings (17) (4) 183 (1,098) 149 Diluted (Loss) Earnings Per Share (0.07) (0.02) 0.72 (4.40) 0.68 CONSOLIDATED BALANCE SHEET DATA Cash and Investments $1,472 $1,706 $1,900 $ 1,423 $ 778 Total Assets 2,780 2,564 2,795 2,188 1,237 Long Term Debt, including current portion5 506 507 682 218 10 Total Shareholders’ Equity 1,571 1,675 1,699 1,677 1,044 1 Includes charges for acquired in-process research and development (IPR&D) in connection with the Company’s acquisition of Cellective on October 14, 2005.
    [Show full text]